Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Bladder Cancer
Interventions
[68Ga]PSMA, PET/CT imaging
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Completed Phase 1 Interventional Results available

Phase I Trial of 225Ac-J591 in Patients With mCRPC

NCT03276572
Conditions
Prostate Cancer
Interventions
225Ac-J591
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
New Orleans, Louisiana • New York, New York
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
68Ga-PSMA-11, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx), Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Metastatic Prostate Cancer
Interventions
[68Ga]PSMA-PET/MRI or PET/CT
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Prostate Cancer
Interventions
177Lu-PSMA-617, 68Ga-PSMA-HBED-CC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • New York, New York
Conditions
Ovarian Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Conditions
Prostate Cancer
Interventions
PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC, PET/CT with Gallium-68 labeled PSMA-HBED-CC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older · Male only
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Guided Stereotactic Body Radiation Therapy, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Recurrent Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography
Other · Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Conditions
Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68GA PSMA-HBED-CC
Drug
Lead sponsor
Jeanne Link
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
Radiation · Other · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
1,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Other · Drug + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography
Procedure · Drug · Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hepatocellular Carcinoma
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Recruiting Phase 3 Interventional Accepts healthy volunteers

PSMA PET Combined With MRI for the Detection of PCa

NCT07052214
Conditions
PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Interventions
68Ga-PSMA-11
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more
Conditions
Thyroid Gland Carcinoma
Interventions
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Active, not recruiting Phase 1 Interventional Results available

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT04506567
Conditions
Prostate Cancer
Interventions
Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg, Fractionated Dose of 225Ac-J591 at 55 KBq/kg, Fractionated Dose of 225Ac-J591 at 60 KBq/kg, Fractionated Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL), Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL), 68Ga-PSMA-HBED-CC injection
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York